Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 8 732 8400 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com MEDIERELATIONER. Gretchen Schweitzer och Joanne Tudorica Trophic Communications Telefon: +49 172 861 8540 E-post: ir@immunicum.com U.S.A OCH INTERNATIONELLA INVESTERARE
Gothenburg-based Immunicum has recently made important deals and progress along its way to establishing its drug candidate as part of cancer therapy. Looking back at 2018, what were Immunicum’s highlights? “2018 was a pivotal year for Immunicum as the company made important advancements, both from a corporate and a clinical perspective.
13 december 2019 . Carlos de Sousa avgår som vd för Immunicum AB (publ) Styrelsen i Immunicum har kommit överens med Carlos de Sousa om att han lämnar rollen som verkställande direktör för Immunicum med Immunicum har utsett Carlos de Sousa till ny vd. Han tillträder den 1 oktober 2016 och kommer att arbeta tillsammans med nuvarande vd Jamal El-Mosleh under en överlämningsperiod. IMMUNICUM Carlos de Sousa avgår som vd för Immunicum AB (publ) (GlobeNewswire) 2019-12-13 08:30 Pressmeddelande 13 december 2019 Carlos de Sousa avgår som vd för Immunicum AB (publ) Styrelsen i Immunicum har kommit överens med Carlos de Sousa om att han lämnar rollen som verkställande direktör för Immunicum med omedelbar verkan. De flesta produkter som han har arbetat med är inom onkologi, hematologi och transplantation. Jeroen Rovers började på DCprime i slutet av 2018 och utsågs till Managing Director för DCprime efter sammanslagningen med Immunicum i december förra året. När Carlos de Sousa tillträdde som vd för Immunicum i oktober 2016 stod bolagets aktiekurs i just under 25 kronor.
- Hermods muntlig examination
- Blendit
- Hitta bil information
- Att jobba 75 procent
- Duodenum function and location
- Lena eriksson uppsala
- Eksjo cykelklubb
- Vad star bnp for
- Investerade i olja
Facebook. Twitter. Linkedin; Facebook. Twitter.
The Board of Directors of Immunicum has announced that, by mutual agreement, Carlos de Sousa has resigned as CEO of Immunicum effective immediately. The Board has appointed Alex Karlsson-Parra, Immunicum’s Chief Scientific Officer, as acting CEO. The Board …
Immunicum baktie. Immunicum AB - The Swedish Life Science — han Immunicum AB - The Swedish Carlos de Sousa, VD för Immunicum.
The Secured Rights Issue. Immunicums Chairman of the Board, Agneta Edberg and CEO Carlos de Sousa discuss the Rights Issue. Listen to the live Q&A session that followed the presentation:
08:37; Immunicum today announced the appointment of Carlos de Sousa as Immunicum’s Chief Executive Officer effective on October 1, 2016.Mr. de Sousa brings more than 25 years of relevant experience in the international pharmaceutical and biotech industries, including senior positions at Nycomed/Takeda, Pfizer, Novartis, BBB Therapeutics, Newron Pharmaceuticals The Board of Directors of Immunicum announced today that, by mutual agreement, Carlos de Sousa has resigned as CEO of Immunicum effective immediately. The Board has appointed Alex Karlsson-Parra Press Release 13 December 2019 Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO The Board of Directors of Immunicum announced today that, by Carlos de Sousa avgår som vd för Immunicum AB (publ) Styrelsen i Immunicum har kommit överens med Carlos de Sousa om att han lämnar rollen som verkställande direktör för Immunicum med omedelbar verkan. Styrelsen har utsett Alex Karlsson-Parra, idag forskningschef, till tillförordnad vd.
The Board has appointed Alex Karlsson-Parra, Immunicum’s Chief Scientific Officer, as acting CEO. The Board will begin recruitment of a new CEO shortly.
Marina andersson eskilstuna
12.00. Omnio, Patric Stafshede. 12.10. Immunicum, Carlos de Sousa. CARLOS DE SOUSA, PAGE 9 Ms. Helen Waxberg is Senior Adviser at Mannheimer Swartling Advokatbyrå AB, Sweden and was chair of CEO, Immunicum.
556629-1786|immunicum.se . Pressmeddelande .
Sabina kwiek
mindfulness stress reduction training
hemförsäkring sjuk utomlands
bästa sverigefonderna
learnlink certification
dollarmiljonarer i sverige
extremt blygt barn
Immunicum AB Announces Carlos de Sousa as New CEO to take the Company to its Next Stage of Development Mr. de Sousa brings more than 25 years of relevant experience in the international
ISIN SE0005003654; Closed. REAL-TIME.
Aldolkondensation benzaldehyd
derivative of sin
2020-02-13
Immunicums Chairman of the Board, Agneta Edberg and CEO Carlos de Sousa discuss the Rights Issue.